Alnylam Pharmaceuticals, Inc.
ALNY
$332.92
$1.680.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.19% | 53.24% | 5.01% | 17.21% | 22.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.19% | 53.24% | 5.01% | 17.21% | 22.97% |
| Cost of Revenue | 110.86% | 68.72% | 32.12% | 2.15% | 4.18% |
| Gross Profit | 57.52% | 50.59% | 0.96% | 20.09% | 26.81% |
| SG&A Expenses | 24.11% | 34.43% | 26.05% | 22.11% | 22.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.46% | 29.02% | 17.86% | 13.05% | 14.91% |
| Operating Income | 383.56% | 240.70% | -275.55% | 34.37% | 37.31% |
| Income Before Tax | 185.63% | 90.05% | -515.19% | -9.44% | 12.95% |
| Income Tax Expenses | 109.48% | -776.59% | -638.08% | -1,268.30% | -1,575.36% |
| Earnings from Continuing Operations | 212.79% | 113.11% | -337.46% | 18.78% | 36.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 212.79% | 113.11% | -337.46% | 18.78% | 36.82% |
| EBIT | 383.56% | 240.70% | -275.55% | 34.37% | 37.31% |
| EBITDA | 563.53% | 342.93% | -178.30% | 52.73% | 47.30% |
| EPS Basic | 209.07% | 111.86% | -330.02% | 21.16% | 38.54% |
| Normalized Basic EPS | 184.53% | 101.63% | -740.52% | -9.88% | 12.84% |
| EPS Diluted | 203.78% | 109.17% | -310.34% | 21.90% | 38.96% |
| Normalized Diluted EPS | 180.47% | 98.02% | -612.07% | -7.18% | 14.43% |
| Average Basic Shares Outstanding | 2.63% | 2.72% | 2.84% | 2.49% | 2.20% |
| Average Diluted Shares Outstanding | 4.57% | 3.88% | 1.61% | 1.25% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |